Image by freepik The composition of gut bacteria can predict which melanoma patients will experience cancer recurrence after surgical resection and immunotherapy, but only when matched to patients with similar microbial profiles, according to research published April 17 in Cell. The findings from a 674-patient international clinical trial offer a novel approach to stratifying recurrence risk in high-risk melanoma patients undergoing adjuvant immune checkpoint blockade. Resear

Squamous cell carcinoma in situ. Photo by Klaus D. Peter via Wikimedia Commons Findings from a preclinical study show a topical cream that blocks the immune-suppressing enzyme LSD1 suppressed tumour growth in two models of cutaneous squamous cell carcinoma (cSCC). The study, published in the Journal of Clinical Investigation , describes how the cream, developed by researchers at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, prevents LSD1

Dr. Antoni Ribas, senior author of the study and director of the UCLA Health Jonsson Comprehensive Cancer Center’s Tumour Immunology...

Elizabeth Burton, PhD. Photo courtesy The University of Texas MD Anderson Cancer Center In a significant advance for the management of...

Researchers at Moffitt Cancer Center in Florida have identified a new strategy to enhance the therapeutic efficacy of immune checkpoint...

Skin lesions on the patient’s forearms were counted before the immunotherapy started, and then again at three, six and 12-month...

In a new study, researchers have identified benefits of SARS-COV-2 mRNA vaccines for cancer patients undergoing immunotherapy. The...

Phase III studies of a personalized vaccine plus immunotherapy for melanoma have been launched at cancer centres around the world,...